JPWO2021020336A1 - - Google Patents

Info

Publication number
JPWO2021020336A1
JPWO2021020336A1 JP2021535323A JP2021535323A JPWO2021020336A1 JP WO2021020336 A1 JPWO2021020336 A1 JP WO2021020336A1 JP 2021535323 A JP2021535323 A JP 2021535323A JP 2021535323 A JP2021535323 A JP 2021535323A JP WO2021020336 A1 JPWO2021020336 A1 JP WO2021020336A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535323A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021020336A1 publication Critical patent/JPWO2021020336A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021535323A 2019-07-26 2020-07-27 Pending JPWO2021020336A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019138041 2019-07-26
US16/835,719 US11083705B2 (en) 2019-07-26 2020-03-31 Pharmaceutical composition for treating tumor
PCT/JP2020/028663 WO2021020336A1 (ja) 2019-07-26 2020-07-27 腫瘍治療用医薬組成物

Publications (1)

Publication Number Publication Date
JPWO2021020336A1 true JPWO2021020336A1 (ja) 2021-02-04

Family

ID=74187564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535323A Pending JPWO2021020336A1 (ja) 2019-07-26 2020-07-27

Country Status (14)

Country Link
US (2) US11083705B2 (ja)
EP (1) EP3970745A4 (ja)
JP (1) JPWO2021020336A1 (ja)
KR (1) KR20220041044A (ja)
CN (1) CN113993545A (ja)
AU (1) AU2020323402A1 (ja)
BR (1) BR112021026170A2 (ja)
CA (1) CA3143486A1 (ja)
IL (1) IL289213A (ja)
MA (1) MA55982A (ja)
MX (1) MX2021016093A (ja)
TW (1) TW202118486A (ja)
WO (1) WO2021020336A1 (ja)
ZA (1) ZA202110686B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2415470T (lt) 2009-03-30 2016-10-10 Eisai R&D Management Co., Ltd. Liposomos kompozicija
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN116407492A (zh) * 2021-12-29 2023-07-11 北京新领先医药科技发展有限公司 一种甲磺酸艾日布林注射液组合物及制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5551683B2 (ja) 1972-10-23 1980-12-25
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
ES2188612T3 (es) 1993-04-22 2003-07-01 Skyepharma Inc Liposomas multivesiculares de ciclodextrina para encapsular compuestos farmacologicos y metodos para su uso.
FR2736056B1 (fr) 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
US6051251A (en) 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
CN1216051C (zh) 1998-06-17 2005-08-24 卫材株式会社 大环类似物及其使用和制备的方法
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
WO2003041682A2 (en) 2001-11-13 2003-05-22 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
US20050118250A1 (en) 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
DE10255106A1 (de) 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
EP1567130A2 (en) 2002-11-26 2005-08-31 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
EP1435231B8 (en) 2002-12-31 2010-03-03 Zydus BSV Pharma Private Limited Non-pegylated long-circulating liposomes
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
JPWO2004089419A1 (ja) 2003-04-04 2006-07-06 国立大学法人 東京大学 抗ｍｔ−ｍｍｐモノクローナル抗体含有脂質膜構造体
US6747011B1 (en) 2003-06-04 2004-06-08 A.P. Group, Inc. Antitumor drugs and methods
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
AU2005207786B2 (en) 2004-01-29 2010-11-25 Eisai R & D Management Co., Ltd Method of stabilizing macrolide compound
CA2821167C (en) 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
AU2005251691A1 (en) 2004-05-17 2005-12-22 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
EP2949652B1 (en) 2004-06-03 2019-08-07 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
US8349360B2 (en) 2004-10-06 2013-01-08 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20090196913A1 (en) 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
BRPI0812913B8 (pt) 2007-06-18 2021-05-25 Merck Sharp & Dohme anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
MX2010003599A (es) 2007-10-03 2010-09-10 Eisai R&D Man Co Ltd Intermediarios y metodos para la sintesis de analogos de halicondrina b.
US20090196918A1 (en) 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5622719B2 (ja) 2009-03-30 2014-11-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
LT2415470T (lt) 2009-03-30 2016-10-10 Eisai R&D Management Co., Ltd. Liposomos kompozicija
JP5388735B2 (ja) 2009-07-21 2014-01-15 浜松ホトニクス株式会社 マイクロチャンネルプレート
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
CA2787919C (en) 2010-01-26 2018-07-31 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
SG10201602147YA (en) 2011-03-18 2016-05-30 Eisai R&D Man Co Ltd Methods And Compositions For Predicting Response To Eribulin
US9220776B2 (en) 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
WO2012139039A2 (en) 2011-04-08 2012-10-11 British Columbia Cancer Agency Branch Bisphenol compounds and methods for their use
EP2734191A4 (en) 2011-07-19 2015-04-29 Stc Unm NANOVÉHICULES ADMINISTERED BY INTERPRETERONAL MOVEMENT RELEASING THEIR THERAPEUTIC LOAD ACCORDING TO THE INFLAMMATORY ENVIRONMENT OF CANCER
KR20190133790A (ko) 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
RU2689977C2 (ru) 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
US20160067337A1 (en) 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
WO2014193898A1 (en) 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
BR112015029386B1 (pt) 2013-06-26 2023-11-14 Eisai R&D Management Co., Ltd. Uso de eribulina e lenvatinibe como terapia de combinação e kit
EP3046543A1 (en) 2013-09-18 2016-07-27 Stc.Unm Torroidal mesoporous silica nanoparticles (tmsnps) and related protocells
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
WO2015095784A1 (en) 2013-12-19 2015-06-25 Luminus Biosciences, Inc. Solid nanoparticle formulation of microtubule inhibitors with reduced ostwald ripening for oral administration
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CA2940983A1 (en) 2014-03-03 2015-09-11 Eisai R&D Management Co., Ltd. Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
EP3114144A1 (en) 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
EP3148336B1 (en) 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CN105640935A (zh) 2014-11-12 2016-06-08 天津市汉康医药生物技术有限公司 供注射用甲磺酸艾日布林药物组合物
AU2016226157B2 (en) 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
WO2018071792A1 (en) 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control

Also Published As

Publication number Publication date
MA55982A (fr) 2022-03-23
TW202118486A (zh) 2021-05-16
KR20220041044A (ko) 2022-03-31
US11083705B2 (en) 2021-08-10
WO2021020336A1 (ja) 2021-02-04
CA3143486A1 (en) 2021-02-04
US20210023047A1 (en) 2021-01-28
BR112021026170A2 (pt) 2022-02-15
IL289213A (en) 2022-02-01
EP3970745A1 (en) 2022-03-23
US20210177802A1 (en) 2021-06-17
CN113993545A (zh) 2022-01-28
EP3970745A4 (en) 2023-07-19
AU2020323402A1 (en) 2022-01-27
MX2021016093A (es) 2022-02-03
ZA202110686B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
BR112021018450A2 (ja)
BR112021017939A2 (ja)
BR112021017738A2 (ja)
BR112021017892A2 (ja)
BR112021017782A2 (ja)
AU2020104490A5 (ja)
BR112021017637A2 (ja)
BR112021018168A2 (ja)
BR112021017728A2 (ja)
BR112021018452A2 (ja)
BR112021017703A2 (ja)
BR112021018102A2 (ja)
BR112021018584A2 (ja)
BR112021018250A2 (ja)
BR112021018084A2 (ja)
BR112021018093A2 (ja)
BR112021018484A2 (ja)
BR112021017732A2 (ja)
BR112021017949A2 (ja)
BR112021017983A2 (ja)
BR112021016996A2 (ja)
AT524962A5 (ja)
BR102019023359A2 (ja)
BR112019016136A2 (ja)
BR112021017847A2 (ja)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805